Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) EBITDA: 2018-2025

Historic EBITDA for Neurogene (NGNE) over the last 5 years, with Sep 2025 value amounting to -$23.8 million.

  • Neurogene's EBITDA fell 7.29% to -$23.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.3 million, marking a year-over-year decrease of 28.33%. This contributed to the annual value of -$82.6 million for FY2024, which is 48.62% down from last year.
  • Neurogene's EBITDA amounted to -$23.8 million in Q3 2025, which was up 8.75% from -$26.1 million recorded in Q2 2025.
  • In the past 5 years, Neurogene's EBITDA registered a high of -$12.6 million during Q2 2023, and its lowest value of -$26.1 million during Q2 2025.
  • In the last 3 years, Neurogene's EBITDA had a median value of -$20.1 million in 2024 and averaged -$19.5 million.
  • Data for Neurogene's EBITDA shows a maximum YoY crashed of 59.84% (in 2024) over the last 5 years.
  • Over the past 3 years, Neurogene's EBITDA (Quarterly) stood at -$14.7 million in 2023, then crashed by 46.01% to -$21.5 million in 2024, then fell by 7.29% to -$23.8 million in 2025.
  • Its EBITDA stands at -$23.8 million for Q3 2025, versus -$26.1 million for Q2 2025 and -$25.9 million for Q1 2025.